Corbus to present updated CRB-701 cancer drug data at ASCO 2026 with expert panel discussion

Corbus Pharmaceuticals will host an in-person and virtual event at ASCO 2026 to present updated Phase 1/2 data on CRB-701, a next-gen antibody-drug conjugate for head and neck squamous cell carcinoma (HNSCC). The data includes clinical response durability and patient subgroup analysis from 75 participants. The event features leading oncology experts and follows recent FDA alignment on CRB-701's regulatory path. This presentation highlights Corbus's progress in developing innovative cancer therapies targeting Nectin-4 expressing tumors.